Uri Lopatin - Assembly Biosciences Insider

ASMB -- USA Stock  

USD 46.96  0.83  1.80%

Vice President - Research & Development, Chief Medical Officer

Dr. Uri Lopatin, M.D. is Vice President Research Development, Chief Medical Officer of ASSEMBLY BIOSCIENCES, Inc. At Assembly Pharmaceuticals, he was Chief Medical Officer and Vice President Research and Development, a position he held since October, 2012. Prior to that, he was a Senior Director for Clinical and Translational ResearchLiver Disease at Gilead Sciences from October, 2010 to September, 2012, a Translational Medical Leader at Roche from May, 2008 to September, 2010. He has designed and coordinated preclinical and clinical collaborations, as well as phase I through IV clinical studies of multiple new molecular entities. Dr. Lopatin has published extensively, especially on hepatitis B and immunology and is an author of multiple patents in the field of treatment and diagnosis for viral hepatitis. Dr. Lopatin received his infectious disease Board certification following fellowship training in ID at the NIH, and internal medicine board certification following completion of residency at NYU. He received his MD in 2000 from University of Medicine and DentistryNew Jersey Medical School.
Age: 42  President Since 2014  Ph.D    
317-210-9311  http://www.assemblybio.com
Lopatin received his infectious disease Board certification following fellowship training in ID at the NIH, and internal medicine board certification following completion of residency at NYU. He received his MD in 2000 from University of Medicine and DentistryNew Jersey Medical School, where he was the recipient of the Stanley S Bergen medal of excellence. He holds a BA in biology from Cornell University, where he graduated cum laude with distinction in all subjects.

Uri Lopatin Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (24.41) % which means that it has lost $24.41 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (44.36) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Entity Summary

Assembly Biosciences, Inc. operates as a clinical stage biotechnology company. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana. Assembly Biosciences operates under Biotechnology classification in USA and traded on Nasdaq Capital Markets. It employs 79 people.Assembly Biosciences (ASMB) is traded on Nasdaq Capital Markets in USA. It is located in NEW YORK, U.S.A and employs 79 people. Assembly Biosciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Assembly Biosciences Leadership Team

Uri Lopatin, President, Ph.D
Helen Kim, Director, MBA
Myron Holubiak, Director
Lee Arnold, Executive, Ph.D
Anthony Altig, Director
Richard Colonno, Executive
Graham Cooper, COO, MBA
William Ringo, Chairman, MBA
Susan Mahony, Director
Richard DiMarchi, Director, Ph.D
Miguel Barbosa, Executive, Ph.D
Thomas Rollins, Executive
Mark Auerbach, Director
Derek Small, CEO
Alan Lewis, Director, Ph.D
David Barrett, COO

Stock Performance Indicators

Current Sentiment - ASMB

Assembly Biosciences Investor Sentiment
Most of Macroaxis users are presently bullish on Assembly Biosciences. What is your sentiment towards investing in Assembly Biosciences? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Assembly Biosciences and NantKwest. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Portfolio Manager module to state of the art portfolio manager to monitor and improve performance of your invested capital.